Nashville Biosciences LLC (NashBio), a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center, and global DNA sequencing giant Illumina Inc.

First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone and with other drug combinations.

THIO has gained its generic name and preclinical data on a different form of the cancer drug suggests it could improve ...

The NIH announced the beginning of a phase 1 first-in-human trial of a vaccine for Lassa fever, a potentially fatal viral hemorrhagic disease for which there is no approved vaccine or treatment.

The company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.

Researchers at the University of Tsukuba have investigated the changes in the primary evaluation items in phase II clinical ...

Discover recent clinical trial failures in depression and explore potential pathways for advancing antidepressant drug ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

Innate Pharma continues its slow rollout of promising clinical candidates, with 2025 set for key milestones. Read more about ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from the brains<a class="excerpt-read-more" href=" More ...

A long-term human trial has found that a discontinued drug halved the presentation of early-onset Alzheimer's disease in ...

The FDA approval of Alnylam’s Amvuttra sets up a three-way race with Pfizer and BridgeBio, which both market transthyretin ...